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ABSTRACT 
Neglected tropical diseases caused by trypanosomatid parasites are a continuing and escalating 
problem, which devastate the less economically developed cultures in countries in which they are 
endemic by impairing both human and animal health. Current drugs for these diseases are regarded 
as out-of-date, expensive, with unacceptable side-effects and mounting parasite resistance, 
meaning there is an urgent need for new therapeutics. Natural products have long been a source of 
potent, structurally diverse bioactive molecules. Herein are reviewed natural products with 
reported trypanocidal activity, which have been clustered based on core structural similarities, to 
aid the future discovery of new trypanocidal core motifs with potential routes to synthetically 
accessible natural product cores suggested.    
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INTRODUCTION 
Trypanosomatid parasites are a group of biochemically related, exclusively parasitic, 
kinetoplastid eukaryotes, in most cases responsible for life threatening and debilitating Neglected 
Tropical Diseases (NTD’s), which affect some of the poorest communities in the world.1 
Encompassed within the family are the causative agents of Human African Trypanosomiasis 
(HAT), namely, two subspecies of Trypanosoma brucei: T. b. gambiense, causing a slow onset, 
chronic form of the disease in 24 countries throughout West and Central Africa, and T. b. 
rhodesiense, causing a fast onset, acute form of the disease in 13 countries throughout Eastern and 
Southern Africa.2–4 Furthermore, the related animal-infective species T. vivax, T. congolense and 
T. brucei brucei, are the most important causative agents of Animal African Trypanosomiasis 
(AAT), locally named nagana in western Africa.5 In both HAT and AAT, parasites are transmitted 
via the bite of the tsetse fly vector (Glossina species).6,7  HAT and AAT are endemic exclusively 
within sub-Saharan Africa where they risk the lives of approximately 65 million people and cause 
economic loss of $4.5 billion per year.8  
In addition to HAT, other trypanosomatid parasites are responsible for Chagas' disease 
(American trypanosomiasis) within South and Central America,9 and leishmaniasis throughout 
southern Europe, south-eastern Asia, Northern Africa and the Americas.10 Chagas' disease is 
caused by the Trypanosoma cruzi parasite, which is transmitted via the triatomine insect vector 
native to America, where an estimated 6 to 7 million people are infected with the disease.9 The 
disease also shows prevalence in North America, primarily in Mexico, with increasingly 
significant numbers of infections in the United States.11 The third human disease caused by 
trypanosomatid parasites, leishmaniasis, is caused by more than 20 different Leishmania species 
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in both the New and Old Worlds, and these include L. amazonensis, L. major, L. infantum and L. 
donovani. The disease is transmitted via the bite of the female phlebotomine sand fly vector, with 
an estimated 300,000 new infections each year and over 1 billion people living in areas at risk, 
primarily throughout the tropics and subtropics.10 
All three human infective diseases, HAT, Chagas' disease and visceral leishmaniasis are deadly 
if untreated. HAT infections are characterized as either early or late stage, with parasites in early 
stage infections being confined to the bloodstream and some intratissue locations, which can 
progress rapidly to the CNS in late-stage infection. Drugs exist to treat both early- and late-stage 
infections; however, due to generic flu-like symptoms of early-stage infection, the disease often 
eludes diagnosis until late-stage infection has been reached, where characteristic symptoms of 
neurological problems and sleep disturbance are presented.6 Most drugs currently approved for the 
treatment of HAT are antiquated, expensive and often have undesirable side effects, with 
increasingly reported drug resistance becoming an urgent issue.12–14 They must be administered 
via injection, which increases treatment costs and risks the spread of other diseases endemic in 
these areas such as hepatitis and the HIV. 15,16 
Chagas' disease reaches the fatal chronic stage in 30-40% of patients infected with T. cruzi 
parasites with the disease commonly going undetected until this stage. Often the disease can take 
many (sometimes as long as 30) years to reach the chronic stage, after which the disease onset is 
rapid and patients die of heart failure caused by parasite damage to the cardiac system, even with 
treatment.9 Treatments for the disease, such as nifurtimox, have unacceptable side-effects and due 
to developing resistance are becoming less effective.17,18  
The fatal visceral form of Leishmania accounts for at least 60,000 deaths per year, with 600 
million people living in at-risk areas. The main effective treatments for visceral infections, are 
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liposomal amphotericin B and meglumine antimonate. Pentavalent antimonials are the standard 
first-line treatment for both visceral and cutaneous leishmaniasis in most parts of the world, but 
they require administration by injection, and the emergence of resistance towards them has limited 
their usefulness. Alternative therapies such as miltefosine, originally an anticancer agent now used 
in the Indian sub-continent for the treatment of leishmaniasis, and paromomycin, an 
aminoglycoside with a defined target, see limited use due to their high costs and poor availability. 
Many of these drugs are only realistically affordable to those in less developed areas through WHO 
programs, by providing the treatments at up to 90% reduced cost.10 As with existing drugs for 
Chagas' disease and HAT, there is increasingly reported parasite resistance and problematic side 
effects accompanying these drugs.19–21  
A combination of treatment pricing, unacceptable side effects and increasing resistance of 
current treatments means there is an urgent need for the discovery of new trypanocidal and 
antileishmanial therapies. Drug development for NTD’s is often overlooked by drug developers, 
with only 4% of treatments developed between 2000 and 2011 targeting these diseases, even 
though they account for 11% of the global disease burden.22 This is mostly due to the fact that 
pharmaceutical companies cannot recover the vast cost of drug development and production for 
such treatments.23,24     
One of the major factors impeding the development of new drugs against trypanosomatid 
diseases is the lack of known effective drug targets. Drug targets must be genetically verified as 
essential and potential inhibitors must be shown to be chemically “on-target” (with validated direct 
inhibition or downstream metabolic disruption of a target protein function) to be effective and 
efficacious for the development of potential treatments. Target determination using known active 
trypanocidal compounds is one approach that would highlight more vitally needed effective drug 
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targets and greatly benefit the design of new treatments. The Drugs for Neglected Diseases 
initiative’s (DNDi’s) guide for drug screening against kinetoplastid diseases states that ideal lead 
compounds against HAT and leishmaniasis must fulfil the following criteria: activity 10 M 
against parasite cells; 10-fold greater potency against parasites versus mammalian cells; the 
biochemical and whole-cell activities must correlate.25 These criteria highlight the need for new 
potent and selective trypanocidal compounds and importantly those which showing chemically 
validated, “on-target” activity.  
Natural products are secondary metabolites produced by organisms in order to provide an 
evolutionary benefit, i.e. an advantage over other competing organisms, often this results in 
chemical compounds that are toxic towards the surrounding organisms. These secondary 
metabolites can be products of various biosynthetic pathways such as polyketide synthases, the 
mevalonate pathway and shikimate pathway. Crossover between separate pathways, as well as 
post-synthetic modifications are often involved to furnish the final bioactive natural product, which 
ultimately generates a wide variety of complex structural motifs, often with potent biological 
activities in various cell types. Due to the nature of their biosynthesis, natural products and their 
medicinally used derivatives typically have lower hydrophobicity and higher stereochemical 
content than purely synthetic compounds.26 These structural features are greatly beneficial in both 
pharmacokinetic parameters and structural diversity of drugs. As a result, natural products have 
been the inspiration for a vast number of current treatments targeting a wide range of diseases, 
with 49% of new drugs from 1981-2014 being natural products or structural derivatives thereof.27 
This places them as promising, largely unexplored, candidates for the identification of new 
trypanocidal drugs, by utilizing common cores observed in trypanocidal natural products, in order 
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to harness their activity, and chemically elaborate to give the required pharmacokinetic parameters 
to be effective new treatments. 
Herein is presented a review of published natural products displaying trypanocidal activity. 
Studies were searched using the National Center for Biotechnology Information’s (NCBI’s) 
PubMed service alongside CAS SciFinder database services searching for the terms 
“Trypanosoma, natural product” and “Leishmania, natural product”.  Compounds mentioned have 
been limited to those showing activity in at least one trypanosomatid cell line below 20 M (within 
2-fold activity of DNDi guidelines for lead candidates) as well as conserved structural 
characteristics shared with other active trypanocidal natural products. The current literature search 
is primarily confined to compounds with trypanocidal activities reported from 2013-2018, 
although some older examples have been included to highlight the recurrence of key motifs. While 
greatly desired, in vivo data for trypanocidal natural products are not widely reported. This is due 
to the high cost of in vivo screening when compared to testing against whole-cell parasite cultures. 
Selectivity data (where available) having a SI value >10 has been deemed preferable, but in many 
cases the selectivity is significantly lower and in some cases favors potency in mammalian cells. 
Initial selectivity of compounds is not strictly necessary however, as often selectivity can be 
engineered into drug scaffolds during optimization through various pathways such as differential 
uptake, metabolism and binding modes.28  
Existing reviews highlighting selected potent natural products against trypanosomatid parasites 
are available. However these often focus on particular sources and do not highlight specific 
skeletons shared between the wide variety of natural products reported.29–31 The primary focus of 
this review is to identify potential synthetically accessible, active core scaffolds which may be 
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beneficial in the identification of new targets as well as the development of potent trypanocidal 
drug compounds.   
 
TRYPANOSOMATID CELL TESTING 
Trypanosomatid parasites have complex life cycles, with various morphologies in both insect 
and mammalian hosts and as a result biological testing can be performed on a variety of parasite 
forms. The most clinically relevant life cycle stage of each parasite are as follows: trypomastigotes 
(bloodstream form) of T. brucei; intracellular amastigotes of T. cruzi; amastigotes of Leishmania 
spp. Due to the significant differences in the environments in which each form of the same parasite 
lives, they each display equally significant biochemical differences, often meaning data between 
life cycle stages is not tractable. A report examining this artefact within a high-throughput screen 
of Leishmania intracellular amastigotes and axenic amastigotes is available.32  In vitro testing of 
intracellular parasites requires compounds to be taken up initially by the mammalian host cell, and 
then by the parasites encompassed within them; making this more indicative of potential in vivo 
results than cell culture testing alone. Testing on intracellular parasites, however, is significantly 
more challenging due to the requirements for parasites to remain virulent against cells, a trait often 
lost in cultured cell lines. Due to the biochemically related nature of each of the parasite species, 
it is plausible that a drug target might be conserved across the trypanosomatid parasites, enabling 
discovery of an active, pan-trypanocidal drug. This is an ideal-world scenario whereas in reality 
even the subtlest of biochemical differences may mean a potent drug in one parasite species may 
be rendered inactive in others. 
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Below (Table 1) is a list of common control drugs and their activities against the relevant parasite 
species and life-cycle stages, to enable comparison of the discussed natural products with typical 
positive control values used within the field. 
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Table 1. Control Drugs Used in Testing of Compounds against the Trypanosomatid Parasites T. 
brucei, T. cruzi, and L. donovani.a 
drug 
T. brucei  
EC50 (M)b 
T. cruzi 
EC50 (M)c 
L. donovani 
EC50 (M) 
L. infantum 
EC50 (M) 
mammalian 
EC50 (M) 
pentamidine 0.0012 (Tbr)12 0.912 
6.4 (P)33 
1.6 (Ax)33 
23.7 (Am)33 
8.3 (P)33 
2.7 (Am)33 
44.1(H)33 
6.4 (V)33 
15.8 (T)34 
melarsoprol 0.01 (Tbg)12     
suramin 0.033 (Tbg)33     
eflornithine 10.6 (Tbr)33     
nifurtimox 2.4 (Tbb)35 1.536 
0.024 (P)34 
0.004 (Am)34 
 
91.2 (H)35 
37.3 (V)12 
benznidazole 30.0 (Tbb)12 9.336    
amphotericin B   
0.07 (P)34 
0.087 (Ax)34 
0.07 (Am)37 
0.04 (P)37 2.0 (T)34 
miltefosine  0.9236 
3.12 (P)33 
2.8 (Ax)33 
2.4 (Am)33 
12.6 (P)33 
4.8 (Am)33 
4.67 (T)34 
paromomycin 22.7 (Tbr)38  
0.005 (P)34 
0.007 (Am)34 
  
 
 
                                                 
a Abbreviations: Tbg, T. b. gambiense; Tbr, T. b. rhodesiense; Tbb, T. b.  brucei; P, promastigote; 
Ax, axenic; Am, amastigote; H, HeLa; V, Vero; T, THP1. 
b T. brucei activities are for bloodstream form parasites. 
c T. cruzi activities are for epimastigote form parasites. 
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FLAVONOIDS 
One of the most common classes of natural products are the flavonoids, many of which have 
been reported to show moderate activity across various trypanocidal parasite species. The FDA 
approved drug flavoxate, used to treat bladder discomfort, is built from a 3-methylflavone scaffold 
implementing it as a valid platform for drug discovery.39 Described below are a selection of 
flavonoids and their derivatives (1-11) shown in in Figure 1.   
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Figure 1. Selected flavonoid natural products 1-11 with reported activity against trypanosomatids. 
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A comprehensive review on trypanocidal flavonoids is available,40 and an extensive structural 
correlation of a set of flavones and their analogues has been investigated by Baldim et al.41 
identifying key SAR characteristics against trypanosomatid parasites. The simplest flavonol (1), a 
constituent of Brassica oleracea,42 has reported pan-trypanocidal activity with EC50 values of 3.0, 
2.2,  and 33.0 M against L. donovani amastigotes, the T. b. rhodesiense bloodstream form and T. 
cruzi intracellular amastigotes, respectively. Compound 1 additionally shows modest selectivity 
with SI values of 21, 29, and 2 for L. donovani, T. brucei and T. cruzi, respectively, as compared 
to L6 cells.40 The closely related flavonol isorhamnetin (2), isolated from a number of sources43–
45 and maintains antiparasitic activities of 11.2 and 12.0 M against the T. brucei bloodstream 
form46 and L. donovani amastigotes, respectively, with no activity in T. cruzi intracellular 
amastigotes up to 90 M. Compound 2 also showed less potency for L6 cells than 1, with SI values 
of 10.7 and 4.6 for L. donovani and T. brucei, respectively.40 Quercetin (3), a constituent of 
numerous plant sources,47–49 differing by removal of a single methyl group, displayed a markedly 
reduced EC50 value of 25.8 M against the T. b. brucei bloodstream form48, however a higher 
potency was observed against L. donovani amastigotes with an EC50 value of 3.3 M.41 3 has also 
been shown to have some in vivo activity against L. donovani amastigotes in mice with 15% 
inhibition observed using a 30 mg/kg dosing regimen over 5 days.40 Its glycosylated analogue, 4, 
isolated from Vangueria edulis, bearing an -linked rhamnose at the 7-hydroxy group, showed 
slightly improved potency against the T. b. brucei bloodstream form with an EC50 value of 20.1 
M.48 The sulfonated myricetin analogue 5, one of a number of flavonoids isolated from the plant 
Limonium caspium, displayed a similar activity of 21.4 M (EC50) against T. brucei, whereas the 
glycosylated variant 6 isolated from the same source showed almost two-fold increased potency 
with an EC50 value of 13.1 M. Both compounds were also tested against L. donovani 
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promastigotes but no activity was reported, with the life cycle stage and subspecies of T. brucei 
not reported.50 The highly methylated flavonol, 7, the most potent in a series of flavones isolated 
from the leaves of the plant species Vitex simplicifolia, gave a moderate potency of 12.1 M (EC50) 
against the clinically relevant T. b. rhodesiense bloodstream form, with a modest SI of 9.8, as 
compared to L6 cells. Various flavones, lacking a 3-hydroxy group, have also been shown to have 
promising potency against trypanosomatid parasites. One relatively simple example, luteolin (8), 
a common flavone isolated from many plant sources, showed low-micromolar inhibition of L. 
donovani amastigotes and the T. b. rhodesiense bloodstream form with EC50 values, in turn, of 2.8 
and 14.1 M. It showed modest selectivity, with SI values of 12 and 3 for L. donovani and T. 
brucei.40 Luteolin (8) and quercetin (3) have been implicated in the induction of topoisomerase II-
mediated DNA cleavage within L. donovani promastigotes and have shown promising in vivo 
activities, with 80% and 90% reduction splenic parasite load compared to PBS, based on a 3.5 
mg/kg and 14.0 mg/kg dose administered twice per week over four weeks in male golden 
hamsters.51 7,8-Dihydroxyflavone (9) is a highly potent flavone derivative, showing 
antileishmanial inhibition of the T. b. rhodesiense bloodstream form having an EC50 value of 0.27 
M and a SI value of 116. Interestingly, the methylated variant, 7,8-dimethoxyflavone (10), 
exhibited a significantly reduced potency with an EC50 value of 21.6 M and SI of 5.40 Finally, 
the isoflavan analogue arizonicanol A (11), isolated with a number of potent 2,5-diphenyl-oxazoles 
from the roots of the plant species Oxytropis lanata, showed good trypanocidal activity, with an 
EC50 of 4.1 M against the  T. congolense bloodstream form, highlighting the potential for further 
core scaffold simplification while maintaining potency.52   
Flavon-3-ol natural products have been shown to inhibit T. brucei pteridine reductase 1 
(TbPTR1), with compounds 1 and 2 showing low micromolar IC50 values of 12.8 and 13.9 M 
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respectively.46 PTR1 has been genetically validated as essential in T. brucei and plays a key role 
for in vivo virulence.53 With their synthetic accessibility, which is discussed later in this review, 
flavonoids are placed as having a potentially strong core structure for the development of future 
lead compounds, and have a strong resource of SAR studies, and examples demonstrating in vivo 
activity and on-target effects against a potential new drug target in T. brucei. Their generally 
modest potency, however, requires vast improvement to attain desirable activity levels for a lead 
drug candidate. 
XANTHONES 
The structurally related class of xanthones is characterized by a core structure containing a 
tricyclic core of two substituted phenyl rings with a central pyrone motif. An extensive review 
examining clinical trials of xanthones is available, which describes their physiochemical and 
pharmacokinetic properties in order to aid the development of lead xanthone-like drug 
candidates.54 The FDA-approved amlexanox, an orally available drug used in the treatment of 
mouth ulcers, bears a structurally related chromeno-pyridinone core, highlighting xanthone-like 
cores as having good pharmacokinetic parameters.39  A number of trypanocidal xanthones have 
been reported, some structurally interesting examples (12-16) are shown below (Figure 2).  
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Figure 2. Selected xanthone natural products (12-16) with reported activity against 
trypanosomatids 
Sterigmatocystin (12), a pentacyclic natural product isolated from a fungal strain from the 
Microthyriaceae order, showed high potency with an EC50 of 0.13 M against T. cruzi amastigotes, 
but along with a strong, undesirable potency for Vero cells with an SI of 0.46.55 The prenylated 
xanthone -mangostin 13 isolated from the pericarp of Garcinia mangostana fruits showed 
impressive pan-trypanocidal activity, with EC50 values of 7.9, 8.9, and 8.0 M respectively for the 
T. brucei bloodstream form, T. cruzi intracellular amastigotes and L. infantum amastigotes. 
However, -mangostin showed a similar potency for MRC-5 leading to SI values of 0.95, 0.84 
and 0.93, respectively.56 The chlorinated xanthone 14 isolated from the fungus Chaetomium sp. 
showed a high potency against T. cruzi intracellular amastigotes and L. donovani promastigotes, 
with EC50 values of 3.8 and 7.9 M, respectively, and good selectivities of 31 for T. cruzi and 6.8 
for L. donovani. Its activity against T. b. rhodesiense bloodstream form was considerably less 
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potent, with an EC50 of 109 M.29 The related structures 15 and 16 isolated along with 14 showed 
potencies against the T. b. rhodesiense bloodstream form in having EC50 values of 13.3 and 19 
M, respectively, with 15 showing no activity in T. cruzi intracellular amastigotes up to 27 M, 
and 16 having an EC50 of 19.8 M. Compounds 15 and 16 showed moderate activities against L. 
donovani promastigotes with EC50 values of 14.3 and 9.6 M, respectively.57  
The pan-trypanocidal nature of many reported xanthones places them as potential interest for 
further evaluation against multiple trypanosomatid cell lines, with overall activities slightly higher 
than those seen in the 3-flavonols. Combined with the vast knowledge accumulated by several 
xanthones progressing through clinical trials for other diseases, this makes them a favourable target 
for further development.  
QUINONES 
Numerous trypanocidal quinones have been reported, with a postulated mode of action of 
naphthoquinones generating reactive oxygen species and inhibiting mitochondrial function within 
the parasites.58,59 Unlike higher eukaryotes such as mammalian cells, which contain thousands of 
mitochondria, trypanosomatid parasites remarkably contain only a single mitochondrion.60 This 
means that they are particularly susceptible to disruption of mitochondrial function, thus this is 
proposed as a potential drug target and putative mechanism toward a selective mode of action.61 
Mitomycin, a FDA-approved quinone natural product, is used as an anticancer therapy, and 
exemplifies the promising pharmacokinetic qualities of this scaffold.39 Structurally interesting 
quinone examples (17-21) have been identified and are discussed below (Figure 3).  
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Figure 3. Selected quinone natural products (17-21) with reported activity against 
trypanosomatids 
Komaroviquinone (17), a potent inhibitor of T. cruzi trypomastigotes, was isolated from the plant 
species Dracocephalum komarovii,62 and has an interesting tetracyclic core structure including a 
1,4-oxygen bridged cyclohept-5,6-ene gave an EC50 value of 0.25 M. An extensive synthetic 
SAR study of komaroviquinone-derived analogues has been completed producing potent 
trypanosomatid inhibitors, of which four displayed submicromolar activities.63 Another tetracyclic 
natural product, the abietane-derived product 18 isolated from the plant species Salvia cuspidata, 
which also shows activity against T. cruzi epimastigotes, although with markedly reduced potency 
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(EC50 of 16.6 M). Three synthetic analogues were prepared from 18, extending from the free 12-
hydroxy motif, the most potent of which being a trimethylsilyl ether showing a more promising 
EC50 value of 5.4 M. All of the examples showed no mammalian activity up to 15 M in Vero 
cells, although this is a low maximum threshold level.64 Even the simple anthraquinone 
damnacanthal (19) showed moderate activity against T. cruzi intracellular amastigotes with an 
EC50 value of 39.5 M but having a low selectivity with a SI value of 0.79.65 Ascidiathiazone A 
(20), a structurally related tricyclic thiazoquinone isolated from the tunicate Aplidium sp., showed 
low micromolar activity against T. b. rhodesiense bloodstream form, with an EC50 value of 3.1 
M, and a high SI of 50 versus L6 cells. This compound exhibited no activity against T. cruzi 
intracellular amastigotes and L. donovani amastigotes up to 250 M. Several synthetic 
thiazoquinone analogues were prepared, with one key example showing sub-micromolar activity 
against T. b. rhodesiense bloodstream form along with increased selectivity, and another showing 
modest pan-trypanocidal activities. In vivo studies were carried out investigating the antimalarial 
activity of 20. A furan ring-based analogue was tested in vivo for activity against P. berghei, and 
gave 85% reduction in parasitaemia for mice using ip injection and 45% reduction on oral 
administration, thereby highlighting the good oral bioavailability of these scaffolds.66 The bis-
glycosylated benzanthraquinone actinosporin A (21), a constituent of the bacterium 
Actinokineospora sp., also demonstrated moderate activity against T. b. brucei bloodstream form, 
with an EC50 value of 15.5 M with a good SI of >13. A compound family member of 21, 
actinosporin B (22), was found to be inactive against the T. b. brucei bloodstream form in the same 
study, and both compounds were reported to show no activity against L. major (the life cycle stage 
was not reported).67 
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Quinones are a reasonably promising class of structurally related trypanocidal compounds, with 
a suggested mode of action inhibiting mitochondrial function; a validated drug target. Due to the 
structural diversity of many of the natural products reported, firm SARs are challenging to 
conclude, although there have been promising correlations found in isolated examples. Related 
thiazoquinones have been shown to have good oral bioavailability through in vivo testing against 
plasmodial parasites. 
INDOLE ALKALOIDS 
Indole alkaloids are a class of natural products typically biosynthesized from tryptophan, and 
they contain an indole moiety furnished with either isoprenyl-derived units or other alkaloid 
moieties. Indole is a key nucleus of many bioactive molecules and natural products and drugs, with 
many indole-containing drugs used in the current market for a wide range of diseases from 
delavirdine as an anti-HIV medicine to binedaline as an antidepressant. A key review on the 
pharmaceutical uses of indoles is available, highlighting the importance of indole-based ring 
systems in existing drugs and pharmaceutical development.68 A number of trypanocidal indole 
alkaloids (23-30, Figure 4) have been collated and are discussed below.  
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Figure 4. Selected indole alkaloids and derivatives (23-32) with reported activity against 
trypanosomatid parasites 
 One of the most common moieties observed in indole alkaloids is the -carboline ring system. 
Opacaline A (23), a brominated -carboline natural product isolated from the ascidian 
Pseudodistoma opacum, showed moderate trypanocidal activity with an EC50 value of 30 M 
against the T. b. rhodesiense bloodstream form and an SI of 2.6 when compared to L6 cells. 
Interestingly, the synthetic de-bromo analogue 24 showed increased potency against T. b. 
rhodesiense bloodstream with an EC50 of 12 M and a modest SI of 7 in comparison to L6 cells. 
Both carbolines 23 and 24 exhibited little or no activity versus T. cruzi intracellular amastigotes 
or L. donovani amastigotes below 100 M.69 Another 6-brominated tryptophan-derived natural 
product, iotrochamide A (25), isolated from the sponge Iotrochota sp., showed potent trypanocidal 
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activity with an EC50 value of 4.7 M against the T. b. brucei bloodstream form and with a good 
SI of >15. The tyrosine-derived analogue iotrochamide B, isolated together with 25, also showed 
similar potency and selectivity, suggesting the eastern fragment of these molecules are crucial for 
activity.70 Neocryptolepine (26), the methylated indoloisoquinoline isolated from the plant species 
Cryptolepis sanguinolenta, showed high to moderate potency against a wide range of 
trypanosomal cells, with EC50 values of 2.2, 2.0, and 49.5 M against T. b. rhodesiense, T. cruzi, 
and L. donovani amastigotes, respectively (the trypanosome life cycle stages were not reported).71 
Modest selectivity was observed with SI values of 2.9, 3.3 and 0.13 for T. b. rhodesiense, T. cruzi, 
and L. donovani amastigotes, respectively. Extensive SAR analysis around the neocryptolepine 
scaffold has been investigated71,72 with numerous analogues being synthetically prepared, of which 
many displayed submicromolar activities against T. b. rhodesiense. The isomeric compound 
cryptolepine (27) isolated from Cryptolepis sanguinolenta,73 showed improved potency against 
both the T. brucei bloodstream form and L. donovani promastigotes, having EC50 values of 0.3 and 
1.6 M respectively. Compound 27, however, also showed higher mammalian cytotoxicity with 
SI values of 29.3 for T. brucei and 0.7 for L. donovani promastigotes as compared to macrophage 
cells. Similarly to 26, various ring substitutions of cryptolepine have been investigated, with a key 
example being 2,7-dibromocryptolepine (28) that showed a considerable potency of 0.0029 M 
against T. brucei bloodstream form and 0.5M against L. donovani promastigotes, with 
exceptional SI values of 2083 and 18, respectively. Furthermore, cryptolepine analogues have 
shown promising in vivo activity against T. brucei in mice with 28 exhibiting similar suppression 
of parasitaemia by oral, im and iv administration.74,75 Fascaplysin (29), a -carboline alkaloid 
isolated from the marine sponge Hyrtios, contains a similar, almost planar structure with only a 
single sp2 carbon center. This compound gave selective, submicromolar, trypanocidal activity with 
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an EC50 value of 0.63 M against T. b. rhodesiense (life cycle stage not reported) and a SI value 
of 16 when compared to L6 cells.76 A structurally related amino-quinoline class of compounds 
named huprines, derived from the naturally occurring huperzines isolated from Huperzia spp.,77 
are known inhibitors of acetylcholinesterase and were developed as a treatment for Alzheimer’s 
disease.78 Huprine Y (30) was determined as the most potent in a series of related natural and 
synthetic compounds when tested against the T. brucei bloodstream form, with an EC50 of 0.6 M 
and a good SI value of 13 versus L6 cells.79 Investigation of synthetic bis-huprines has also been 
undertaken, with examples retaining similar potency, however, with increased selectivity.80  
The manzamines are a family of over 100 complex -carboline-containing natural products 
isolated from a variety of marine sponges, which as a family have shown broad bioactivity and 
importantly antileishmanial activity.  A comprehensive review on the manzamine alkaloid family 
and their antileishmanial activity is available.81 One key example, manzamine A (31), was first 
isolated from a sponge of the genus Haliclona and in addition to its known anticancer activity, 
possesses potent antileishmanial activity with an EC50 of 1.6 M against L. donovani 
promastigotes. This alkaloid displayed significant cytotoxic activity against Vero cells, however, 
and gave a SI of just 1.3.82 Another key example, the structurally related compound manzamine X 
(32), first isolated from a Xestospongia sp. Sponge,83 showed modest antileishmanial activity with 
an EC50 value of 9.8 M against L. donovani promastigotes, although with no discernible 
cytotoxicity towards Vero cells.82  
Diketopiperazines (DKPs) are a common motif within natural products, originating from the 
cyclization of two amino-acid partners during biosynthesis. Tadalafil, marketed under the name 
Cialis, is an FDA approved, orally administered treatment for erectile dysfunction, which contains 
an indole-linked DKP motif and highlights the usefulness of this core as a drug platform.39 Notable 
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trypanocidal indole-linked DKPs have been reported, and some examples (33-36, Figure 5) are 
discussed below.  
 
 
Figure 5. Selected indole-containing DKP natural products (33-36) with reported activity against 
trypanosomatids 
12,13-Dihydroxyfumitremorgin C (33), one of a number of polycyclic DKPs isolated from 
Aspergillus fumigatus, displayed good antitrypanosomal activity, with an EC50 value of 6.4 M 
against the T. b. brucei bloodstream form and having an SI of 15 when compared to Jurkat cells.84 
The structurally related spirocyclic 6-methoxyspirotrypostatin B (34) and 
dehydrobis(methylthio)gliotoxin (35), isolated from the same organism showed similar whole-cell 
activity with EC50 values of 5.7 and 8.5 M, respectively, against the T. b. brucei bloodstream 
form. Both exhibited modest respective SI values of 3.7 and 16.6 when compared to Jurkat cells. 
 24 
Compounds 33 and 35 were shown to inhibit T. b. rhodesiense cysteine protease with IC50 values 
of 10.9 and 19.5 M, respectively. Compound 34 showed no enzymatic inhibition up to 50 M.84 
Although non-essential, cysteine protease has been suggested to play a role in the migration of the 
parasites across the blood-brain barrier, making it a target worthy of further investigation.85 
Verticillin B (36) a complex indole-containing DKP with an interesting disulfide-bridging 
functionality, isolated from the fungus Nectria inventa, showed extremely potent activity against 
T. b. brucei, with an EC50 value of 0.007 M. This compound did, however, exhibit considerable 
cytotoxicity with an EC50 of <0.6 M against Jurkat cells. A number of other disulfide-bridged 
DKPs were also isolated in the same study and displayed equally high levels of trypanocidal 
potency, but also high cytotoxicity demonstrating this as a highly potent but generally cytotoxic 
motif.84 
A wide range of structurally diverse, trypanocidal, indole-containing natural products has been 
reported in the recent literature. Examples such as the cryptolepine, neocryptolepine and related 
quinone huprine scaffolds have been subjected to SAR studies, highlighting key trends for both 
trypanocidal and leishmanicidal activity. Coupled with the promising in vivo activity of 
cryptolepine analogues and ongoing development of huprines as potential Alzheimer’s disease 
treatments, there is a solid foundation for the further development of such core structures into 
active antiparasitic compounds. Additionally, indole-containing DKP scaffolds have been shown 
to be modest inhibitors of T. b. rhodesiense cysteine protease, which is influential in the 
progression of this parasitic disease to the later CNS stage, which may be exploited to prolong the 
lifetime of first-stage treatments.   
SESQUITERPENE DERIVATIVES 
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Terpene-derived natural products encompass a wide range of skeletal motifs, based upon the 
number of isoprene units encompassed within the molecule and further structural modifications. 
Numerous trypanocidal terpenoids have been reported, with many sharing a common 7,5 or 6,6-
membered, fused ring system, and a number of examples [37-43, Figure 6 and 44-49 Figure 7] are 
discussed below.  
 
Figure 6. Selected structurally related sesquiterpene and iridoid natural products (37-43) with 
reported activity against trypanosomatids 
Psilostachyin (37), a sesquiterpene lactone isolated from the plant species Ambrosia tenuifolia, 
displayed potent inhibition of T. cruzi, with EC50 values of 4.3 and 12.5 M against the 
epimastigote and trypomastigote forms, respectively, and L. mexicana promastigotes with an EC50 
value of 0.42 M. The SI values against L6 cells were 21 and 34 for T. cruzi epimastigotes and 
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trypomastigotes and 214 for L. mexicana.86 The related natural product family member, 
psilostachyin C (38), isolated from Ambrosia sabra showed more potent activity against T. cruzi 
cells with EC50 values of 2.3 and 3.4 M against epimastigote and intracellular amastigotes as well 
as 4.5 and 5.7 M for L. mexicana and L. amazonensis promastigotes.87 Compounds 37 and 38 
have both been found to display in vivo activity against T. cruzi in mice. Of these, compound 37 
gave an approximately 1.5-fold reduction in parasitaemia over acute infection (up to 30 days), and 
100% survival rate up to 50 days.86 In line, 38 gave a two-fold reduction in parasitaemia over acute 
infection and a 20% survival rate over the first 30 days.87 Both compounds out-performed the 
current treatment benznidazole in these studies, in which all mice treated with this drug died by 
day 35 for the psilostachyin (37) study and 30 for the psilostachyin C (38) study. In both studies, 
the sesquiterpenes and benznidazole were given by ip administration as a 5-day treatment of 1 
mg/kg per day. The modes of action of 37 and 38 have been explored in T. cruzi and are reported 
to induce trypanosome death by independent modes of action, with the suggested mechanism 
action of 37 being heme interaction and of 38 being inhibition of sterol synthesis.88 This could 
explain the significant differences of in vivo activity between these two structurally similar 
compounds. The related lactone vernolepin (39), the most potent of four sesquiterpene lactones 
isolated from the plant Veronia sp., showed a very high activity and a good selectivity against the 
T. brucei bloodstream form, with an EC50 of 0.19 M and SI of 14.5 as compared to L6 cells.89 A 
guaianolide (40) isolated from the plant Tanacetum parthenium, which bears a 5-7-5 fused tricyclic 
core structure, gave a moderate trypanocidal activity against both the T. cruzi epimastigote and 
trypomastigote forms with EC50 values of 18.1 and 5.7 M, respectively, but an EC50 value of only 
67 M against intracellular amastigotes. Compound 40 showed fairly low cytotoxicity with good 
SI values of 5.2, 16 and 1.4 against the epimastigote, trypomastigote and intracellular amastigote 
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forms, respectively, when compared to LLCMK2 cells. Some synergistic effects were observed 
between this guaianolide and benznidazole with epimastigotes, and investigations into phenotypic 
effects on parasite cells have suggested that trypanocidal action occurs through multiple 
mechanisms.90 The carboxylic acid 41, isolated from the plant Eupatorium perfoliatum, which 
bears the same 5-7-5 core structure, showed no inhibition against either T. cruzi or L. donovani. It 
was, however, determined as a moderate inhibitor of the T. b. rhodesiense bloodstream form 
growth, with an EC50 of 20.7 M and a SI of 11 when compared to L6 cells. The related compound 
42, a suspected dimeric product of 41, and isolated from the same source, displayed an increased 
potency against the T. b. rhodesiense bloodstream form with an EC50 of 4.5 M, and additionally 
demonstrated modest potency against both T. cruzi intracellular amastigotes and L. donovani 
amastigotes, with EC50 values of 30.3 and 10.2 M, respectively. The selectivity of 42 was poor, 
with SI values of 2.6, <1 and 1.6 for the T. b. rhodesiense bloodstream form, T. cruzi intracellular 
amastigotes, and L. donovani amastigotes, respectively.91 Molucidin (43), the parent compound of 
a series of iridoids isolated from the tropical plant species Morinda lucida, which despite being 
skeletally distinctive from compounds 37-42, also contains a highly oxygenated, fused polycyclic 
core and showed submicromolar potency against T. b. brucei cells with an EC50 value of 1.2 M, 
with a modest SI of 11.2 as compared to HF-19 cells.92 Phenotypic investigation into trypanosome 
death by treatment with molucidin analogues has shown flagellar deformation as well as cell cycle 
alteration as possible modes of action. In the same study, the free acid of 43 was tested for in vivo 
activity, giving complete clearance of parasitemia in mice for 20 days post-infection based on five 
consecutive daily doses of 30 mg/kg. Molducin, however showed significant toxicity and caused 
death of the mice at day 7.93 
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Figure 7. Further selected sesquiterpene natural products and synthetic derivatives (44-49) with 
reported activity against trypanosomatids 
Nobilin (44), a natural product isolated from Anthemis nobilis, displays a 5-10 fused core 
structure related to the 5-7-5 core observed for other trypanocidal sesquiterpenes. It exhibited 
potent trypanocidal activity with an EC50 value of 3.2 M against the T. b. rhodesiense bloodstream 
form with a modest SI of 2.1 when compared to L6 cells. A number of synthetic transannular 
cyclization products of nobilin have also been investigated, revealing several antitrypanosomal 
compounds, the most potent of which, 45, showed near ten-fold increased activity over nobilin, 
with an EC50 of 0.46 M and a similar SI of 2.4.94 A related natural product deoxyelephantopin 
(46), was identified through a bioassay-guided isolation from the tropical plant species 
Elephantopus scaber, which contains an additional lactone ring, forming a 5-10-5 fused ring 
system. This compound displayed a very high potency against the T. b rhodesiense bloodstream 
form, with an EC50 value of 0.07 M, and a high SI of 65 as compared to L6 cells.95 A number of 
elephantopin derivatives have been reported previously, displaying potent antileishmanial 
activities, with the parent compound and others having EC50 values of <0.28 M against L. major 
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promastigotes. It has been reported that the -methylene--lactone moiety is a key factor in 
mediating the anti-trypanosomal activity of sesquiterpene derivatives.96 This is well-known to act 
as a strong Michael acceptor, leading to inactivation of the trypanothione cycle, a key aspect in 
regulating peroxide levels within trypanosomatids, which therefore induces oxidative stress.95,97 
4-Acetoxydolastane (47), a natural product isolated from the marine alga Canistrocarpus 
cervicornis bearing a 6-7-5 fused cyclic core, displayed potent antileishmanial activity with EC50 
values of 5.5 and 18 M, respectively, against L. amazonensis promastigote and intracellular 
amastigote forms. Additionally, 47 exhibited low cytotoxicity, with a selectivity index of 93 versus 
J774G8 macrophages. Investigation of its mechanism of action revealed induction of 
ultrastructural changes, including mitochondrial damage, suggesting interference with the 
mitochondrial membrane potential.98 Shagene A (48), a terpenoid isolated from an undescribed 
coral genus also displayed inhibitory activity against Leishmania, with an EC50 of 5 M against L. 
donovani intracellular amastigotes, with no observed cytotoxicity, and a SI value of >70.99 
Interestingly, an almost identical keto variant, shagene B (49), displayed no trypanocidal nor 
cytotoxic activity, a drastic effect from minimal structural alteration, alluding to the importance of 
the methoxy group substituent.99  
The terpenoid lactones are a quite diverse class of natural products, although many of those 
active against trypanosomatid parasites are somewhat closely related in structure. Seemingly key 
to their activity is the presence of an exocyclic methylene substituent at the -position of five-
membered lactone ring. Additionally, 5-10 type fused ring systems seem to be common bioactive 
cores, with several examples displaying submicromolar activities. Mode of action studies have 
been carried out on some key structures, suggesting interference with trypanosome oxidant 
regulation and the resultant induction of oxidative stress. Along with promising in vivo results for 
 30 
one reported compound, this overall class should provide additional promising leads for the further 
development of new trypanocidal and leishmanicidal compounds.  
GUANIDINE ALKALOIDS 
Guanidine alkaloids are relatively common natural products, and many have been reported to 
show trypanocidal activity, with several of those extracted from marine sources appearing to be 
particularly potent. A number of guanidine alkaloids of interest (50-54, Figure 8) are discussed 
below.  
 
 
Figure 8. Selected guanidine alkaloid natural products (50-56) with reported activity against 
trypanosomatids 
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The relatively simple molecule monalidine A (50), one of several guanidine alkaloids isolated 
from the marine sponge Monanchora arbuscular, showed potent activity against both T. cruzi 
trypomastigotes and L. infantum promastigotes with EC50 values of 8 and 2 M, respectively. 
along with moderate SI values of 3 and 13, respectively, using LLC-MK2 cells. In the same study, 
the more complex dimer batzelladine L (51), isolated from the same source, showed improved 
activity against T. cruzi promastigotes, with an EC50 value of 2 M, and retained antileishmanial 
activity (EC50 of 2 M) and having SI of values of 11 for both parasite species.100 Synthetically 
prepared agelasine D (52), first isolated from the sponge Agelas nakamurai,101 while not 
containing a guanidine moiety, displays a close chemical analogue in its adenine core, which has 
been suggested to aid its uptake via P2 transporters. It exhibited potent pan-trypanocidal activity 
against the T. b. brucei bloodstream form, T. cruzi intracellular amastigotes, and L. infantum 
amastigotes, with EC50 values, in turn, of 1.8, 9.0, and 3.0 M, and SI values of 5, 2 and 6.7, 
respectively, as compared to MRC-5 cells. Investigation of several agelasine D structural 
analogues highlighted this core structure as having potential for trypanocidal and leishmanicidal 
activity, with many compounds surpassing the potency of the parent natural product. One key 
example (53) showed potent activity with EC50 values of 0.5, <0.25 and 2 M for the T. b. brucei 
bloodstream form, T. cruzi intracellular amastigotes, and L. infantum amastigotes, respectively. 
However, significant cytotoxicity was also shown, with corresponding SI values of 1.8, <3.6 and 
0.45 as compared to MRC-5 cells.102  
The simple 2-amino-imidazole-containing fragment-like natural product 54, one in a series of 
imidazolium compounds isolated from Agelas oroides, also showed modest pan-trypanocidal 
activity against the T. b. rhodesiense bloodstream form, T. cruzi intracellular amastigotes and L. 
donovani amastigotes, with reported EC50 values of 17, 18, and 95 M, respectively. However, it 
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exhibited high cytotoxicity in L6 cells, with SI values, in turn, of 3, 3 and 0.05. Compound 54, 
along with other imidazolium compounds in the series, was revealed as an enoyl reductase 
inhibitor in the related protozoan species Plasmodium falciparum, suggesting this as a potential 
mechanism of action, although this has not been described in trypanosomatids.103 Sceptrin (55), a 
bromo-imidazole natural product containing an interesting tetrasubstituted cyclobutane core, was 
originally isolated from Agelas sceptrum.104 It showed modest potency against the T. b. 
rhodesiense bloodstream form, with an EC50 value of 15.7 M, in addition to low toxicity in L6 
cells with an SI value of >10. This substance, however, showed little activity against T. cruzi 
intracellular amastigotes and L. donovani amastigotes (EC50 values of 96 M and 83 M, 
respectively).105 Dibromopalau’amine (56), a complex dibrominated polycyclic natural product 
extracted from the sponge Anixella verrucosa106 bears similar amino-imidazolium moieties to 55. 
It proved to be a submicromolar inhibitor of the T. b. rhodesiense bloodstream form, with an EC50 
value of 0.8 M, and demonstrated potent inhibition of L. donovani amastigotes (EC50 value of 
1.9 M) but low activity for T. cruzi intracellular amastigotes (EC50 value of 120 M). This 
compound showed modest selectivity for both T. b. rhodesiense and L. donovani, with SI values 
of 10 and 4 respectively.105  
Examples of guanidine-derived and related alkaloids have been shown to be potent inhibitors of 
individual trypanosomatid species and are modest pan-trypanocidal agents. Although existing 
SAR and in vivo studies are limited in this class of alkaloids, preliminary studies have shown some 
success. The adenosine-derived natural product agelasine D (52) showed low micromolar 
inhibition of all three parasite species investigated, and a follow-up study of synthetic analogues 
has yielded submicromolar inhibitors of T. brucei and T. cruzi. Despite the unfortunate 
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accompanying cytotoxicity thus far shown by these analogues, their scaffold presents a good basis 
for further development of trypanocidal agents.   
ENDOPEROXIDES 
The endoperoxide motif exemplifies the diverse three-dimensional structural nature of bioactive 
natural products. Its functionality is rarely seen in synthetic drug compounds, yet is a recurrent 
feature in reported highly trypanocidal natural products, many of which are isolated from marine 
animals. Examples of some endoperoxide-containing natural products (57-64) are shown in Figure 
9. Interestingly FDA-approved drugs artemether and arteether, and the natural product from which 
they are derived, artemisinin, all contain an endoperoxide functionality and are all used as frontline 
treatments for malaria, a related neglected tropical disease caused by Plasmodium falciparum.39,107 
This highlights the moiety as a feasible active core in the treatment of other NTD’s such as those 
caused by the trypanosomatids.       
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Figure 9. Selected endoperoxide-containing natural products (57-64) with reported activity 
against trypanosomatids 
Manadoperoxide B (57), an endoperoxide isolated from the sponge Plakortis cf. lita showed 
submicromolar potency against the T. b. rhodesiense bloodstream form with an EC50 value of 
0.0088 M. Compound 57 additionally showed very high selectivity with an SI value of >3000 as 
compared to HMEC cells.108 The hydrolyzed variant, manadoperoxidic acid (58), also isolated 
from the Plakortis cf. lita sponge, showed somewhat reduced activity with an EC50 value of 5.7 
M and only moderate selectivity (SI value of 3.8 compared with L6 cells). 12-Isomanadoperoxide 
B (59), the Z-isomer of manadoperoxide B (57), isolated from Plakortis cf. lita, showed a slight 
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reduction in potency but still exhibited submicromolar inhibition of the T. b. rhodesiense 
bloodstream form with an EC50 value of 0.032 M and a SI value of >350 when compared to L6 
cells.109 The structurally related plakortide P (60), isolated from the sponge Plakortis 
angulospiculatus showed modest potency against T. cruzi trypomastigotes with an EC50 value of 
6.3 M. The compound, however, exhibited poor selectivity when compared to the other 
structurally related endoperoxides discussed, with an SI value of 7.110 11,12-Dehydro-13-oxo-
plakortide Q (61) and manadoperoxide I (62), isolated from the sponges Plakortis 
angulospiculatus and Plakortis cf. lita respectively, have shown the tolerance of varying 
appendages to the endoperoxide core. Compounds 61 and 62 have reported activities against the 
T. b. brucei and T. b. rhodesiense bloodstream form parasites with respective EC50 values of 0.049 
and 0.17 M, and SI values of 105 as compared to HEK-293 cells for 61 and >160 as compared 
to HMEC cells for 62.108,111 Isolation and testing of a range of manadoperoxides are described by 
Chianese et al.108 Ergosterol peroxide (63), a sterol isolated from Pleurotus ostreatus and Trametes 
versicolor, showed trypanocidal and leishmanicidal activities with EC50 values of 16.8, 13.9, and 
4.0 M against T. cruzi epimastigotes, L. amazonensis promastigotes, and L. amazonensis 
amastigotes, respectively. Sterol 63 showed only modest selectivity, with SI values of >5, 3, and 
11 for T. cruzi, L. amazonensis promastigotes, and L. amazonensis amastigotes, respectively.112,113 
Ergosterol is the dominant de novo synthesized sterol in trypanosomatids, and has been 
implemented in signaling for the regulation of T. brucei growth, potentially alluding to the 
trypanocidal activity of 63.114 Plakortide E (64), isolated from the sponge Plakortis 
halichondroides, possesses a five-membered endoperoxide core as opposed to the six-membered 
core displayed in compounds 57-63. Compound 64 showed activity against T. brucei with an EC50 
value of 5 M and an SI of >20 compared to J744.1 macrophages, but no activity against L. major 
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promastigote cells. Plakortide E (64) has been shown to be a non-competitive, reversible inhibitor 
of the trypanosomatid cysteine protease, rhodesain, in addition to similar cysteine proteases from 
other species.115 This suggests a similar mode of action for other endoperoxides, although further 
investigation into structure-activity relationships is required.  
Endoperoxides comprise a range of extremely potent trypanocidal compounds, with many 
examples showing submicromolar activity. Manadoperoxides, in particular, have been revealed as 
being very potent, with some key SAR factors and structural tolerances already revealed. While 
seemingly complex, these core structures can be readily accessed synthetically, as discussed later 
in this review. Insights into their suspected mode of action, via the inhibition of cysteine proteases, 
requires further investigation as well as analysis of their in vivo performance against parasitic 
infections. 
MACROCYCLES  
Macrocycles are a diverse branch of natural products, encompassing cyclic secondary 
metabolites with rings comprising of 12 or more atoms. Various trypanocidal macrocycles have 
been reported, with selected examples (65-71) shown in Figure 10.  
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Figure 10. Selected macrocyclic natural products (65-71) with reported activity against 
trypanosomatids 
Cembrane-type diterpenes are a class of macrocyclic natural products typically comprising a 14-
membered cycle often fused with furanyl rings or bridged at various ring positions. A key 
collection of antiprotozoal cembrane diterpenes is available,116 with important examples of the 
family being laevigatol B (65) and laevigatol A (66). Laevigatol B (65), isolated from the coral 
Lobophytum crassum and Lobophytum laevigatum117 showed trypanocidal activity against the T. 
b. brucei bloodstream form with an EC50 value of 5.3 M, and SI of >20 as when comparing to 
the HEK293T and HepG2 cell lines.  Additionally, 65 showed weak activity against T. cruzi 
 38 
intracellular amastigotes, with a 15.2% reduction in cell viability at 50 M.118 Interestingly, 
laevigatol A (66), the epoxidated analogue of 65 exhibited no reported activity against T. b. brucei 
up to 20 M.116 Lobocrasol A, 67, a structurally related macrocycle isolated from Lobophytum 
crassum117 displayed potent leishmanicidal activity and moderate trypanocidal activity with EC50 
values of 0.18 and 10.0 M against L. donovani amastigotes and the T. b. rhodesiense bloodstream 
form with SI values of 310 and 6, respectively, as compared to L6 cells. Hypothemycin (68), a 14-
membered, macrolactone featuring a fused phenolic substituent isolated from the fungi Hypomyces 
trichothecoides,119,120 Coriolus versicolor,121 and Aigialus parvus122 showed potent activity against 
the T. brucei bloodstream form with an EC50 value of ~0.17 M. In vivo investigation of its activity 
showed a 33% cure rate of mice infected with T. brucei, based on a 10 mg/kg dose administered 
once daily for 7 days. At doses higher than 10 mg/kg, however, significant signs of toxicity were 
observed in the mice, likely due to the known covalent inhibition of CDX kinases by 
hypothemycin.123,124 Further to this known activity, the trypanocidal mechanism of 68 was 
investigated, revealing covalent inhibition of TbCLK1 kinase with a recorded IC50 value of 0.15 
M.124 No selectivity data have been reported, and the competing activity in human kinases could 
be problematic in further development. 
Bastimolide A (69), a 40-membered macrolide isolated from the marine cyanobacterium 
Okeania hirsute, showed multi-trypanocidal activity against both T. cruzi intracellular amastigotes 
and L. donovani amastigotes with EC50 values of 6.5 and 3.0 M, respectively. However, 
compound 69 showed somewhat low selectivity with SI values of 2 and 1 for T. cruzi and L. 
donovani, respectively, as compared to Vero cells.125 Lobosamides A and B (70 and 71) are 26-
membered polyene macrolactams isolated from the actinobacterium Micromonospora species, 
varying only by a single alkene geometry. Lactam 70 showed submicromolar potency against T. 
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b. brucei with an EC50 value of 0.8 M, whereas 71 exhibited an almost 10-fold reduced activity 
of 6.1 M. Both had low toxicity to T98G mammalian cells, with SI values of 83 and 11 for 
compounds 70 and 71, respectively. Other macrolactams isolated together with Lobosomides A 
and B showed no trypanocidal activity despite their structural similarities.126  
Macrocyclic natural products have contributed several low and submicromolar trypanocidal 
compounds, some with high selectivity indices versus mammalian cells. Larger macrocycles, such 
as bastimolide, present a significant challenge in their synthesis and investigation of SAR, due to 
their large size and high flexibility. Smaller macrocycles such as the cembrane-type diterpenes are 
more appropriate for such studies, as many structurally related examples are known, some with 
reported trypanocidal activities. This foundation of knowledge can help build SAR correlations 
for further investigations into the activity of this core structure. However their synthesis remains 
challenging and requires intelligent route planning to achieve systematic SAR analyses.   
CYCLIC PEPTIDES 
A wide range of cyclic peptides are known, with varying reported biological activities, ranging 
from beneficial antibiotics to potent neurotoxins. Cyclic peptides vary in ring size, comprised 
primarily of amino-acid building blocks, which are cyclized either through the peptide backbone 
or by secondary linkages through side chains.  Various trypanocidal natural cyclic peptides have 
been reported, a number of which (72-77) are shown in Figure 11. It should be noted that many of 
the trypanocidal cyclic peptides reported show accompanying antiplasmodial activity.  
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Figure 11. Selected natural cyclic peptides (72-77) with reported activity against trypanosomatid 
parasites 
Venturamides A and B (72 and 73), two cyclic hexapeptides isolated from the cyanobacterium 
Oscillatoria species, display an interesting mixed oxazole and thiazole containing core, with a 
singular alanine/threonine variation differentiating the two. Both showed moderate 
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antitrypanosomal activity with EC50 values against T. cruzi intracellular amastigotes of 14.6 and 
15.8 M for compounds 72 and 73, respectively, but showed no detectable leishmanicidal activity 
against L. donovani amastigotes up to 20 M. They both exhibited low cytotoxicity with moderate 
SI values 6 and 3.5 for 72 and 73, respectively, for T. cruzi amastigotes when compared to Vero 
cells.127 The structurally related hexapeptide aerucyclamide C (74), the most potent in a family of 
cyclic peptides isolated from the cyanobacteria Microcystis aeruginosa, similarly contains both 
oxazole and thiazole motifs, with the addition of a methyl-oxazoline replacing one thiazoles 
moiety. It showed moderate trypanocidal activity against the T. b. rhodesiense bloodstream form, 
with an EC50 value of 9.2 M, and good selectivity with an SI value of 12 compared to L6 cells.128 
The parent compound family member, aerucyclamide A (75), also isolated from Microcystis 
aeruginosa,129 showed almost two-fold reduced trypanocidal activity, with an EC50 value of 15.9 
M, but maintained moderate selectivity with an SI of 8.128  
The large peptide tachyplesin I (76), isolated from the crab species Tachypleus tridentatus,130 
comprises a 17 amino acid chain bicyclic structure, cyclized through  two pairs of  cysteine-
cysteine disulfide bridges. It displayed good leishmanicidal activity with an EC50 value of 9.3 M 
against L. braziliensis promastigote cells and moderate trypanocidal activities with EC50 values of 
9.3 and 47.9 M for T. cruzi trypomastigote and epimastigote cells, respectively.131 These 
activities surpass the previously known antifungal and antibacterial activities of 76,130 but remain 
only modest in comparison to other trypanocidal natural products. Valinomycin (76), a known 
antibiotic and potassium (K+) ionophore originally isolated from Streptomyces fulvissimus,132 
consists of a 12-membered depsipeptide core, consisting of D- and L-valine, D--hydroxyisovaleric 
acid and L-lactic acid moieties. Compound 77 showed potent antitrypanosomal and antileishmanial 
properties, with EC50 values of 0.0032 M  and <0.11 M for the T. b. brucei bloodstream form 
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and L. major promastigotes, respectively, with very high selectivity (SI values of 3500 and >100 
for T. b. brucei and L. major, when compared to 293T cells).133  
Despite the potent trypanocidal and leishmanicidal activity of cyclic peptides, they present a 
challenging structural core for further development. Peptide chemical synthesis is challenging and 
tedious, with very poor atom economies on regularly applied routes. Desirable promiscuous 
enzymatic processes are needed to produce the wide variety of cyclic peptides required for a 
systematic SAR study are not yet available. Few trypanocidal cyclic peptides have been 
investigated with the focus of elucidating their mechanisms of action, a key factor that must first 
be tackled in order to develop them further as trypanocidal agents.   
FASCILITATING DEVELOPMENT THROUGH ACCESSIBILITY 
The discovery of new drug targets for trypanocidal agents is vital to the development of new and 
improved therapeutics that are more appropriate for modern medicinal use than those currently 
administered. To facilitate this process, therapeutic scaffolds must be easily synthesized and 
chemically modified to allow their further furnishing with a wide variety of moieties and 
functionalities. This enables the generation of SAR correlations, in addition to the tailoring of 
pharmacokinetic characteristics such as logP, oral bioavailability, protein binding and metabolic 
stability. One key derivatization step is to allow the conjugation of biochemical tags, which may 
be used to aid target identification, localization and uptake studies of potential therapeutics. An 
extensive review of the methods available for the use of various approaches to identify drug modes 
of action has been published by our group.134 Key applicable techniques include the use of 
photoaffinity labeling chemistry to covalently link modified lead compounds to their target, 
enabling subsequent target identification by mass spectrometry or selective isolation using an 
installed chemical tag.  
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For these techniques, isolation of natural products from their natural sources is often not a viable 
option. This is because yields of many isolated natural compounds such as artemisinin, paclitaxel, 
and various antibiotics are normally low and may be from limited natural resources. Chemical 
modification of existing natural products is limited by existing functional groups and is often 
challenging. Synthetically accessible natural product cores that retain the trypanocidal activity of 
parent natural products are beneficial in this aspect, as they can be designed to contain chemical 
handles for further modification. Unlike natural products themselves, however, cores can also be 
designed with synthetic tractability in mind, enabling rapid synthesis for SAR and target 
identification studies. 
We have suggested routes by which common trypanocidal cores highlighted in this study might 
be accessed, enabling the synthesis of furnished cores to further examine modes of action. These 
routes are shown in Figure 12. 
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Figure 12. Common trypanocidal natural product cores and suggested synthetic routes by which 
they may be accessed through precedented chemistry 
Flavone and flavonol syntheses are well-known chemical routes, where a variety of o-
hydroxyacetophenones may undergo an aldol condensation with a corresponding benzaldehyde to 
form 2-hydroxychalcone derivatives. Chalcones can be either cyclized with molecular iodine to 
form flavones, or via the Algar-Flynn-Oyamada reaction with hydrogen peroxide to give the 
corresponding flavonol. This approach has previously been used by Lam et al. using a range of 
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substituted benzaldehydes and acetophenones in the combinatorial generation of a library of 
various flavones and flavonol derivatives.135  
The formation of -carboline ring systems can be accessed via an acid-catalyzed Pictet-Spengler 
condensation of tryptophan with various aldehydes, giving the corresponding tetrahydro--
carboline unit. This reaction has a wide substrate scope, where additional substitution on the indole 
moiety and various aldehydes are tolerated. In some cases, the aldehyde component may be 
replaced with a ketone, giving the corresponding 1,1-disubstituted -carboline unit.136 Further 
oxidation of the monosubstituted tetrahydro--carboline ring system can be performed using 
hypervalent iodine reagents to give fully conjugated variants. Decarboxylative ring oxidation 
occurs where the naked carboxylic acid moiety originating from tryptophan is present during the 
oxidation reaction, although it is prevented via simple esterification or further derivatization at this 
position.137 
1,2-Dioxane derivatives can be accessed through the modification of various ,-unsaturated 
aldehydes through initial modification via Ragoussis’ modified Knoevenagel condensation to form 
the corresponding skipped diene.138 Dienes can then be converted to the 4,5-unsaturated 1,2-
dioxane systems through reaction with photo-generated singlet oxygen species.139 Various 
aldehydes can be utilized in the Knoevenagel condensation, or the diene could be installed via 
Wittig reaction of phosphonium ylides, giving a very wide scope of possible substitutions. Further 
functionalization of the alkene of the 4,5-dehydro-1,2-dioxane core, such as reduction with 
Adam’s catalyst (PtO2)/H2,140 or dihydroxylation with OsO4,141 are additional options for 
molecular derivatization. A recent study by Taglialatela-Scafati et al. investigated a range of 1,2-
dioxane derivatives accessed via similar routes for their antiplasmodial activities.142 The stability 
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of the endoperoxide group to further functional group interconversions is surprising. During the 
total synthesis of plakortide E by Sun et al., early installation of the 1,2-dioxolane motif was 
followed by exposure to various harsh chemical reagents including borohydride reduction, n-
butyllithium, and tin hydride reagents, with reactions proceeding with moderate to high yields.143 
EXAMPLES OF APPLYING TRYPANOCIDAL NATURAL PRODUCT CORES 
The concept of applying active natural product cores in the development of trypanocidal 
compounds, as well as aiding identification of novel targets has already been applied. Two 
examples are shown in Figure 13. In the case of convolutamine I (78), an antitrypanosomal alkaloid 
from the bryozoan Amithia tortusa,144 a potency and pharmacokinetic-based SAR study examined 
analogues of 78. Through the study, a new lead, 79, was developed that showed increased potency 
with an EC50 value of 0.5 M, as compared to the isolated natural product EC50 value of 1.1 M, 
and exhibited a significantly improved pharmacokinetic profile.145  
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 Figure 13. Examples utilizing natural product cores to improve synthetic accessibility, drug-
likeness and selectivity while maintaining trypanocidal activity 
Chamuvarinin (80), an acetogenin isolated from the plant species Uvaria chamae,146 which bears 
a tri-heterocyclic core, was the subject of an extensive SAR study, with the use of a synthetically 
accessible core analogous to that of the natural product. In this study, compounds maintaining the 
low micromolar activity of the natural product (EC50 of 1.3 M vs. the T. b. brucei bloodstream 
form and a SI value of 2 vs. HeLa cells)147 while significantly improving synthetic accessibility 
and importantly selectivity towards mammalian cells were synthesized. Compound 81, one such 
example, exhibits pan-trypanocidal activity, with EC50 values of  5.1, 12.7, and 15.3 M for T. b. 
brucei, T. cruzi epimastigotes, and L. major promastigotes, respectively, with SI values of 100, 39 
and 33 as compared to Vero cells.148 
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MODIFICATION OF NATURAL PRODUCT CORES 
Natural products often do not follow the Lipinski “rule of 5”, however, many are already in use 
as potent drugs for a variety of diseases.149,150 This should be noted in the further development of 
key natural product cores, where factors such as logP, plasma protein binding and solubility should 
be monitored, however strict adherence to Lipinski rules is not absolutely necessary.  
For natural products where simple or reliable chemical synthesis methods are not viable, for 
example, in the case of small cyclic peptides and macrocycles, heterologous expression in 
laboratory-culturable systems is a valid alternative. In such systems, it is preferable that enzymes 
along the biosynthetic pathway show some promiscuity, allowing the introduction of modified 
substrates furnishing the desired products with chemically modifiable handles. This approach has 
already been shown in the modification of a range of natural products,151 as well as biologically 
active cyclic peptides.152,153    
CONCLUSIONS 
Natural products historically are an important source of biologically active structures for the 
development of treatments for a wide range of human and animal diseases. The natural product 
structures described in this review show that certain natural product scaffolds hold great potential 
for the pursuit of potent trypanocidal compounds, with many compounds having low or 
submicromolar activities against some, or even all three kinetoplastid species, while still 
maintaining favorable selectivity. Some key scaffolds uphold the strong reputation of favorable 
bioavailability of natural products through their promising in vivo activities, but this number is 
relatively small. A priority of further research should be to investigate further those promising 
leads that have not yet been tested in vivo.  Furthermore, the recurrence of certain core moieties 
throughout the large number of trypanocidal compounds examined shows several active compound 
 49 
skeletons, some with desirable three-dimensional characteristics often lacking in purely synthetic 
libraries, which should be investigated further in the development of urgently required antiparasitic 
therapies, and also be key players in the discovery of novel drug targets.  Chemical tractability of 
these scaffolds will allow easy and rapid structure activity relationships to be explored, as well as 
informed positioning of fluorescent and/or affinity tags, to aid uptake, mode of action studies and 
target identification studies. 
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